An open label study of the effect of Xeloda and radiotherapy on pathological response rate in patients with locally advanced rectal cancer.
- Registry ID
- EUCTR2008-003980-38
- Source registry
- EUCTR
- Status
- Completed
- Phase
- PHASE2
- Sponsor
- Roche Slovensko s.r.o.
- Start date
- 2008-09-22
- Last update
- 2026-08-16
Conditions
- Locally advanced rectal cancer
Summary
To determine the pathological complete response (pCR) rate in patients treated with capecitabine plus standard radiotherapy of the pelvic region followed by surgery
Locations
View on source registry